These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 7533359

  • 1. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A.
    Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmüller T, Christe W, Hopf U, Lobeck H, Neuhaus P.
    Transplant Proc; 1995 Feb; 27(1):1117-20. PubMed ID: 7533359
    [No Abstract] [Full Text] [Related]

  • 2. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
    Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Lobeck H, Hop U, Neuhaus P.
    Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 4. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
    Bechstein WO, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Ericzon BG, Bismuth H.
    Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
    [No Abstract] [Full Text] [Related]

  • 5. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB.
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC, Theilmann L.
    Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
    [No Abstract] [Full Text] [Related]

  • 8. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP, Tullius SG, Mueller AR, Schumacher G, Nüssler N, Neuhaus R, Bechstein WO, Lobeck H, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients.
    Takahara S, Kokado Y, Kameoka H, Takano Y, Moutabarrik A, Jiang H, Ishibashi M, Okuyama A, Nishi Y, Chiba N.
    Transplant Proc; 1994 Oct; 26(5):2802-6. PubMed ID: 7524219
    [No Abstract] [Full Text] [Related]

  • 10. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients.
    Platz KP, Mueller AR, Bechstein WO, Blumhardt G, Neuhaus P.
    Transplant Proc; 1994 Dec; 26(6):3133-4. PubMed ID: 7527952
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
    [Abstract] [Full Text] [Related]

  • 13. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
    Wiesner RH, Porayko MK, Wahlstrom HE, Gores GJ, Kamath PS, Hay JE, Krom RA.
    Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
    [No Abstract] [Full Text] [Related]

  • 14. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
    [No Abstract] [Full Text] [Related]

  • 15. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group.
    Transplant Proc; 1994 Dec; 26(6):3260-3. PubMed ID: 7527960
    [No Abstract] [Full Text] [Related]

  • 16. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
    Mueller AR, Platz KP, Berg T, Fukomoto T, Guckelberger O, Neuhaus R, Bechstein WO, Hopf U, Lobeck H, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
    [No Abstract] [Full Text] [Related]

  • 17. Short- and long-term cyclosporine dosage in liver transplantation.
    McCaughan GW, Bookallil MJ, Sheil AG.
    Transplant Proc; 1994 Oct; 26(5):2674-5. PubMed ID: 7940837
    [No Abstract] [Full Text] [Related]

  • 18. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506?
    Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmüller T, Christe W, Hopf U, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Jun; 9(3 Pt 1):176-84. PubMed ID: 7549057
    [Abstract] [Full Text] [Related]

  • 19. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group.
    Wiesner RH.
    Transplant Proc; 1998 Jun; 30(4):1399-400. PubMed ID: 9636565
    [No Abstract] [Full Text] [Related]

  • 20. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES, So S, Jendrisak MD, Perdrizet GA, White HM, Marsh JW.
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.